Positive new data have been released on a drug candidate, RPC1063, for relapsing multiple sclerosis. According to the results from a six-month Phase 2 study of 258 multiple sclerosis patients, the drug candidate reduced the annualized relapse rate of participants with multiple sclerosis by up to 53 percent, compared with placebo. The potential therapy also decreased the emergence of new brain damage seen by MRI by more than 90 percent.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/VQiK1MoN9lI/140919092755.htm
MS drug candidate shows new promise
19 septiembre 2014
Volver